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ResearchUndetectable plasma viral load predicts normal 
survival in HIV-2-infected people in a West African 
village
Maarten F Schim van der Loeff†1, Natasha Larke†2, Steve Kaye1, Neil Berry3, Koya Ariyoshi4, Abraham Alabi1, Carla van 
Tienen1, Aleksandra Leligdowicz1, Ramu Sarge-Njie1, Zacharias da Silva5, Assan Jaye1, Dominique Ricard1, 
Tim Vincent5, Sarah Rowland Jones1, Peter Aaby5, Shabbar Jaffar2 and Hilton Whittle*1
Abstract
Background: There have been no previous studies of the long-term survival and temporal changes in plasma viral 
load among HIV-2 infected subjects.
Methods: 133 HIV-2 infected and 158 HIV-uninfected subjects from a rural area in North-west Guinea-Bissau, West 
Africa were enrolled into a prospective cohort study in 1991 and followed-up to mid-2009. Data were collected on four 
occasions during that period on HIV antibodies, CD4% and HIV-2 plasma viral load.
Results: Median age (interquartile range [IQR]) of HIV-2 infected subjects at time of enrollment was 47 (36, 60) years, 
similar to that of HIV-uninfected control subjects, 49 (38, 62) (p = 0.4). Median (IQR) plasma viral load and CD4 
percentage were 347 (50, 4,300) copies/ml and 29 (22, 35) respectively.
Overall loss to follow-up to assess vital status was small, at 6.7% and 6.3% for HIV-2 infected and uninfected subjects
respectively. An additional 17 (12.8%) and 16 (10.1%) of HIV-2 infected and uninfected subjects respectively were
censored during follow-up due to infection with HIV-1. The mortality rate per 100 person-years (95% CI) was 4.5 (3.6,
5.8) among HIV-2 infected subjects compared to 2.1 (1.6, 2.9) among HIV-uninfected (age-sex adjusted rate ratio 1.9
(1.3, 2.8, p < 0.001) representing a 2-fold excess mortality rate associated with HIV-2 infection.
Viral load measurements were available for 98%, 78%, 77% and 61% HIV-2 infected subjects who were alive and had
not become super-infected with HIV-1, in 1991, 1996, 2003 and 2006 respectively. Median plasma viral load (RNA
copies per ml) (IQR) did not change significantly over time, being 150 (50, 1,554; n = 77) in 1996, 203 (50, 2,837; n = 47)
in 2003 and 171 (50, 497; n = 31) in 2006. Thirty seven percent of HIV-2 subjects had undetectable viraemia (<100
copies/ml) at baseline: strikingly, mortality in this group was similar to that of the general population.
Conclusions: A substantial proportion of HIV-2 infected subjects in this cohort have stable plasma viral load, and those 
with an undetectable viral load (37%) at study entry had a normal survival rate. However, the sequential laboratory 
findings need to be interpreted with caution given the number of individuals who could not be re-examined.
Background
The sooty mangabey simian immunodeficiency virus
(SIV), the ancestor of HIV-2, is estimated to have crossed
from monkey to man around 1940, resulting in an out-
break of HIV-2 subtype A in West Africa [1]. HIV-2 has
remained endemic in West Africa, and now in this region
both HIV-2 and HIV-1 infections are prevalent, providing
an opportunity to draw comparisons between the natural
history and immunopathogenesis of the two viruses [2].
A prevalence of HIV-2 of 8-10% has been recorded in
some settings [3], but is now thought to be stable or fall-
ing across West Africa [4]. Median survival of HIV-1
infected subjects in sub-Saharan Africa in the absence of
antiretroviral therapy is about 10 years [5,6], similar to
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that in developed countries, and plasma viral load and
CD4 count have been identified as strong markers of
prognosis [7,8]. Because of the paucity of community-
based HIV-2 cohorts, median survival with HIV-2 has
not been widely documented, but survival with HIV-2
was longer than that with HIV-1 in a hospital-based study
in Gambia, especially at higher CD4 count [9,10]. Simi-
larly, in an urban community-based study among individ-
uals more than 35 years old [11], 9-year HIV-2-associated
mortality was only twice that of HIV-uninfected subjects
[12]. The long-term survival of HIV-2 infected subjects is
not known.
A number of studies have shown that HIV-2 infections
are associated with lower plasma viral load [13], slower
CD4 decline [14,15] and a lower incidence of AIDS [16]
than HIV-1 in the same study populations. Also, CD4
count and plasma viral load in HIV-2 are predictors of
mortality [17-20]. However, some of this evidence is from
hospital-based studies which contained subjects with
more advanced disease with a relatively short follow-up
period. Whether these markers predict survival over the
long-term in the community or the clinic is not known.
We have conducted a community-based cohort study
of HIV-2 infected people in rural West Africa followed
from 1991 through to 2009. Here we report changes in
plasma viral load and survival over this 18-year follow-
up, which is the longest on record and one of the few with
laboratory variables.
Methods
Study area and population
The study was conducted in Caió, a village in north-west-
ern Guinea-Bissau, West Africa. The study comprised a
population of about 10,000 individuals, mostly subsis-
tence farmers. The sex ratio is unbalanced because many
men migrate for work. Women may also leave in search
for work in the region's urban centres.
A serological survey conducted in the community
between 1989-1991 showed HIV-2 prevalence among
adults aged ≥ 15 years to be 8% (240 subjects), peaking at
19% in men aged 45-54 years, and 17% in women aged
35-44 years [21]. HIV-2 infected subjects and an equal
number of HIV-seronegative controls, broadly matched
for age and sex, were visited at home by field staff. Those
who were present at home and gave informed consent
were invited to participate in the study [22]. Field staff
were unaware of the HIV status of the study subjects.
Subjects were followed-up annually to record vital sta-
tus (data collected up until mid-2009). They were also
invited for a clinical examination and asked for a blood
sample in 1991, 1996, 2003 and 2006. Blood samples were
tested for HIV status, and those HIV-infected were tested
for CD4% and plasma viral load.
All subjects received pre-test counselling before HIV
testing during each of the four study rounds. Post-test
counselling and HIV test results were available for those
who wanted to know their results. Subjects had access to
a physician-led clinic and were offered free medical treat-
ment, including that for anaemia, malaria, and syphilis,
according to national guidelines. Prophylaxis against
opportunistic infections with co-trimoxazole was offered
from 1999 onwards to HIV infected subjects who were
aware of their diagnosis and who were either symptom-
atic or had a CD4% <28%. Antiretroviral treatment was
not available in Guinea-Bissau at the time of the field
study, but is now in place.
Laboratory methods
The laboratory methods of the 1991 and 1996 study
rounds are described by Wilkins et al. [21], Ricard et al.
[22] and Berry et al. [20]; methods for 2003 and 2006 are
described in Leligdowicz et al. [23]. In brief, for measur-
ing HIV-2 plasma viral loads in 2003 and 2006, RNA was
extracted from 200 μl plasma using a silica gel purifica-
tion method, and an aliquot of the extract equivalent to
40 μl of the original sample was amplified in a single-tube
reverse transcribed-PCR (Qiagen "One-Step", Hilden,
Germany). A standard curve was generated using RNA
extracted from cell culture supernatants of HIV-2 (strain
CBL-23). Each reaction was spiked with approximately
100 copies of an internal control. This control was a 1 kb
RNA molecular construct spanning the PCR primer
binding sites and replacing the probe binding site with a
25 base randomised sequence. The control was extracted
and co-amplified with the test sample and probed sepa-
rately. Results were calculated as signal ratios of test sam-
ple to internal control and copy numbers determined by
comparison with the standard curve. A positive control
was included in every assay run to control for inter-assay
variation. The assay had a dynamic range of 100 to
1,000,000 RNA copies/ml of plasma. Samples with unde-
tectable virus were assigned a value half that of the detec-
tion threshold of the test, for the purposes of analysis.
Twenty-nine samples of HIV-2 infected subjects taken
in 1996 were re-assayed with the current method. The
mean virus loads were 3.81 log10 and 3.96 log10 copies/ml
by old and current method respectively. Fifteen (52%)
were less than 0.5 log10 different, and 25 (86%) were
within 1 log10 difference; the agreement was acceptable
[beta = 0.75 (95%CI 0.48, 1.02); r2 = 0.55].
We chose to analyse the CD4 data by percentage rather
than by absolute count. In the early years of the epidemic,
due to the lack of automated counting machines, we were
obliged to estimate lymphocyte counts by manual meth-
ods which introduced considerable observer variation
and error. Moreover a batch of slides from Caio destined
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for lymphocyte counting was damaged during transit on
bad roads. Thus in addition to providing a more robust
measurement, the use of CD4 percentage obtained by
FACS analysis allowed us to use the full data set at base-
line.
Ethics
This study was approved by the MRC Laboratories/Gam-
bia Government Joint Ethics Committee, the London
School of Hygiene & Tropical Medicine Ethics Commit-
tee, and the Research Committee of the Ministry of
Health of Guinea-Bissau.
Statistical methods
Continuous data were presented as medians and inter-
quartile ranges (IQR), since these data were non-nor-
mally distributed. Continuous data were compared
between groups using the Wilcoxon rank sum or Kruskal-
Wallis test. Categorical data were compared using the
chi-squared test. Correlation was assessed using Spear-
man's correlation coefficient. Mortality rates were calcu-
lated using Poisson regression with time calculated from
enrolment in 1991 to either the date of death or the end of
the study in mid-2009 or the last date seen alive for those
lost-to-follow-up (i.e. permanently moved away from the
village or were not re-identified). HIV-2 infected subjects
who also seroconverted to HIV-1 in a subsequent survey
were censored from the date on which they were known
to be infected with HIV-1. Controls who seroconverted to
either HIV-1 or HIV-2 were censored likewise. Analyses
were conducted using Stata 10 (Stata Corp, College Sta-
tion, TX, USA).
Results
Baseline characteristics
In 1991, 133 HIV-2 infected and 158 HIV-uninfected
subjects were enrolled. Almost all were from the Manjago
ethnic group (Table 1). Median age (Interquartile range
[IQR]) of HIV-2 infected subjects was 47 (36, 60) com-
pared with 49 (38, 62) of HIV-uninfected subjects (p =
0.4). The male: female ratio was similar among HIV-2
infected and HIV-uninfected subjects (p = 0.4). Among
HIV-2 infected subjects median (IQR) plasma viral load
and CD4 percentage were 347 (50, 4,300) copies per ml
and 29 (22, 35). Forty eight of the 130 subjects (37%) who
were tested had an undetectable level of virus (<100 cop-
ies/ml), whereas only 22 (17%) had levels above 10,000
copies/ml. The median viral load was lower among
women (137, IQR 50, 127,000) compared to men (755,
IQR 125, 286,000). Plasma viral load was associated
inversely with CD4 percentage (r = -0.30, p < 0.001) but
not with age (r = 0.07, p = 0.4).
Follow-up and survival of HIV-2 and HIV-uninfected 
subjects
Subjects were followed-up annually through to mid-2009,
with blood samples collected in 1991, 1996, 2003 and
2006 (Figure 1). Loss to follow-up with regard to vital sta-
tus was small, being 6.7% and 6.3% respectively for the
infected and uninfected subjects respectively. In addition
a further 17 (12.8%) HIV-2 infected and 16 (10.1%) unin-
fected subjects became infected with HIV-1 during fol-
low-up. The proportion of HIV-2 infected and HIV-
uninfected subjects known to be alive in 1996, 2003, 2006
and 2008/9 and who did not seroconvert to HIV-1 were
74% and 83%, 46% and 66%, 38% and 60%, and 31% and
53% respectively. The median (IQR) follow-up time was
11.8 (5.3, 17.3) years among HIV-2 infected subjects and
17.7 (9.5, 18.6) among HIV-uninfected subjects (p <
0.001).
Baseline characteristics of those followed-up success-
fully through to 2008/09, those who died and those lost to
follow-up or censored are shown in Table 2. The distribu-
tion of age, sex, percentage CD4 and plasma viral load of
those alive were similar to those lost to follow-up or cen-
sored, but differed substantially from those who died.
The overall mortality rate per 100 person-years (95% CI)
was 4.5 (3.6, 5.8) among HIV-2 infected subjects com-
pared to 2.1 (1.6, 2.9) among the HIV-uninfected popula-
tion. Figure 2 shows the Kaplan-Meier survival of HIV-2
and HIV-uninfected subjects. Mortality increased with
age and was higher among men than women, but this was
true for both HIV-infected and HIV-uninfected subjects
(Table 3). Thus the relative difference or rate ratio
decreased with age. Among subjects 60 years or older in
1991, there was no significant difference in survival
between HIV-2 and HIV-uninfected. Overall, the mortal-
ity rate ratio (95% CI) adjusted for age category and sex
was 1.9 (1.3, 2.8, p < 0.001). Mortality rates for both
groups were marginally higher during 1999 to 2009 com-
pared to the earlier time period (Table 3). The mortality
of women compared with men was 0.42 (95% CI 0.24,
0.74) among HIV-uninfected subjects after adjusting for
age category and 0.51 (95% CI 0.31, 84) among HIV-2-
infected.
Association between baseline CD4 percentage, plasma 
viral load and the mortality of HIV-2 infected subjects
In the univariable analysis both plasma viral load and
CD4 percentage were associated independently with
mortality (Table 4). The association with plasma viral
load was very strong (Figure 2). Mortality in those with
undetectable viral load was similar to that of the unin-
fected subjects, whereas those with a viral load of 10,000
copies/ml or greater had a rate of 10.4 per 100 years,
which is similar to that for HIV-1 in the region [11].
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In a multivariable analysis with age category, sex,
plasma viral load category and CD4 percentage category,
the association between mortality and plasma viral load
became stronger. The adjusted rate ratio for the medium
viral load category (101-10,000 copies/ml) was 2.0
(95%CI 1.0, 4.2) and 5.6 (95%CI 2.5,12.5) for the high viral
load category ( > 10,000 copies/ml). When plasma viral
load was analysed on a continuum, the adjusted mortality
ratio was 1.8 (95%CI 1.4, 2.3; p < 0.0001) for every log10
increase in viral load.
In the multivariable analysis, there was no evidence of
an association between CD4 percentage and mortality.
The adjusted rate ratio for those with a CD4 percentage
<28% compared with ≥ 28% was 1.4 (95% C I 0.8, 2.5; p =
0.2). When CD4 percentage was analysed on a contin-
uum, the adjusted mortality rate ratio was 1.3 (95% C I
0.98,1.7: p = 0.07) for every absolute 10% decrease in
CD4.
Changes in HIV-2 plasma viral load and CD4% over time
Table 5 shows the plasma viral load and CD4% among
HIV-2 infected subjects during follow-up. The propor-
tion of HIV-2 infected subjects who were alive and had
not been censored due to loss to follow-up or HIV-1 sero-
conversion, from whom viral load was available in 1991,
1996, 2003, and 2006 were 98%, 78%, 77% and 61%
respectively; the corresponding proportions for CD4
measurements were 94%, 74%, 72% and 61%. The median
plasma viral load of those tested did not differ signifi-
cantly between the time points (p = 0.5) whereas the
median CD4% showed a small increase over time (p =
0.01). Plasma viral load measured in 1996, 2003 and 2006
was correlated with baseline (1996: r = 0.68, p < 0.001, n =
76; 2003: r = 0.53, p < 0.001, n = 47; 2006: r = 0.38, p =
0.04, n = 31), although this correlation decreased over
time.
Changes in plasma viral load over time were also analy-
sed according to follow-up status (died, lost to follow-up
or censored, and alive). The median change between 1991
and 2003 among those alive in 2006 was 0 (IQR -57, 657
copies per ml; n = 27), and this was similar to those who
were lost to follow-up or censored (0, IQR -632, 1082
copies per ml; n = 12) (p = 0.8). The median change
between 1991 and 2003 for those who died after 2003 was
20,236 (IQR -780, 57,328 copies per ml; n= 6) (p = 0.1).
Thirty-one subjects had plasma viral load measure-
ments, and 30 were tested for CD4% in both 1991 and
2006. Their median (IQR) age at baseline was 46 (41, 57)
years. The median (IQR) plasma viral load was 105 (50,
335) and 171 (50, 497) copies per ml respectively and
median (IQR) CD4 percentage 29% (25, 35) and 33% (27,
42) respectively. Fifteen (48%) had undetectable plasma
viral load in 1991, of whom 13 (42%) had maintained an
undetectable viral load 15 years later in 2006.
Discussion
The disease course and pathogenicity of HIV-2 infections
are recognised to differ from HIV-1, although detailed
descriptions of long-term survival with HIV-2 over pro-
longed periods have not been fully documented. In this
unique 18-year community-based study conducted in
rural Guinea -Bissau, we have demonstrated the mortality
of HIV-2 infected subjects to be approximately twice that
of HIV-uninfected subjects. This confirms findings from
Table 1: Baseline characteristics in 1991.
HIV-2 infected
(N = 133)
Uninfected 
(N = 158)
Age in years a
<30 13 (10%) 29 (18%)
30-39 24 (18%) 27 (17%)
40-49 39 (30%) 31 (20%)
50-59 20 (15%) 32 (20%)
60-69 28 (21%) 20 (13%)
≥ 70 8 (6%) 19 (12%)
Sex
Males 42 (32%) 43 (27%)
Ethnicityb
Manjago 125 (94%) 152 (96%)
Other 7 (5%) 6 (4%)
a Data missing for one HIV-2 infected subject
b Data missing for one HIV-2 infected subject
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studies which had shorter durations of follow-up
[9,10,12,20,22] and extends the earlier observations of
this cohort [20]. Mortality rate ratios of HIV-2-infected
and HIV-uninfected decreased with age (at enrolment).
In fact the rate ratios diminished with time either because
background mortality of the elderly is high or because
many of the HIV-2 infected old people were long term
non-progressors with a normal lifespan. Mortality, after
adjusting for age, was lower in women than men who also
have higher plasma viral load. In contrast mortality in
rural Uganda was increased 10 fold in HIV-1 infected
subjects and was similar for men and women. In the
Ugandan study, those over the age of 55 years died more
rapidly than younger patients or their age matched unin-
fected counterparts [6].
Ascertainment of vital status was good in this close-
knit rural West African community, with a total loss to
follow up of only 6.5%. However, follow up sampling for
laboratory tests was less satisfactory as, apart from those
who died, many subjects were not in the village at the
time of the surveys or were identified to have serocon-
verted to HIV-1, so were censored. Thus, the longitudinal
aspects of the laboratory studies need to be interpreted
with some caution as the outcomes of those not retested
Figure 1 Flowchart showing follow-up status of subjects with respect to biological measurements and survival over the course of the 
study. At some time points subjects were known to be alive e.g. they were seen at later time points, but measurements were not taken from them. a 
After 2006 biological measurements were not taken and so data on seroconversions not available between 2006 and 2009. b Subjects who had died 
by mid-2009. c Known to be alive at latest census in 2009.
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are not known (though their baseline characteristics were
broadly similar to those who were re-sampled). In addi-
tion we do not know precisely when the subjects in our
cohort were infected with HIV-2, but even if infection
was acquired recently and the death rate was high among
those lost to follow-up, our study confirms that many
HIV-2 infected subjects may have a long-lifespan.
Baseline plasma viral load among our HIV-2 cohort was
generally very low as previously reported [20]. Plasma
viral load was undetectable in 37% of the subjects who
had a normal lifespan; this is in sharp contrast to almost
all community-based HIV-1 studies in Africa. For exam-
ple, in a study among pregnant women in Gambia only
3% of HIV-1 infected subjects had an undetectable viral
load, and the median viral load was 30-40 fold higher
Table 2: Baseline characteristics (in 1991) of subjects according to HIV diagnosis and follow-up status in 2008/09.
HIV-2 infected HIV-uninfected
Alive in mid 
2009 (N = 41)
Died by mid 
2009 (N = 66)
Lost or 
censored by 
mid 2009 
(N = 26)
Alive in mid 
2009 (N = 83)
Died by mid 
2009 (N = 49)
Lost or 
censored by 
mid 2009 
(N = 26)
Sex, number 
(%)
Male 12 (29) 27 (64) 3 (7) 18 (42) 20 (47) 5 (12)
Female 29 (32) 39 (43) 23 (25) 65 (57) 29 (25) 21 (18)
Age in years, 
median (IQR)
45 (33, 55) 56 (42, 66) 43 (37, 49) 41 (28, 52) 63 (51, 71) 42 (37, 53)
CD4 
percentage, 
median (IQR)
32 (25, 40) 25 (18, 32) 32 (26, 35)
Plasma viral 
load copies 
per ml, 
median (IQR)
79 (50, 775) 1630 (127, 
12,225)
90 (50, 530)
Table 3: Crude mortality rates by age and sex among HIV-2 - infected and HIV uninfected individuals.
HIV-2 infected HIV-uninfected
Number died/
total per 
category (%)
Mortality rate 
per 100 person-
years (95% CI)
Number died/
total per 
category (%)
Mortality rate 
per 100 person-
years (95% CI)
Rate ratio (95% 
CI)
Age groupa, b
<40 15/37 (41) 3.4 (2.0, 5.6) 7/56 (13) 0.8 (0.4, 1.7) 4.2 (1.7, 10.2)
40-59 23/59 (39) 3.4 (2.3, 5.1) 15/63 (24) 1.6 (1.0, 2.7) 2.1 (1.1, 4.1)
≥ 60 28/36 (78) 8.5 (5.9, 12.3) 27/39 (69) 5.8 (4.0, 8.5) 1.5 (0.9, 2.5)
Sex
Male 27/42 (64) 6.1 (4.2, 8.8) 20/43 (46) 3.7 (2.4, 5.8) 1.6 (0.9, 2.9)
Female 39/91 (43) 3.9 (2.8, 5.3) 29/115 (25) 1.7 (1.2, 2.4) 2.3 (1.4, 3.7)
Calendar time
1991-1998 37/133 (28) 4.3 (3.1, 6.0) 24/158 (15) 1.9 (1.3, 2.8) 2.3 (1.4, 3.8)
1999-2009 29/84 (35) 4.8 (3.4, 7.0) 25/120 (21) 2.5 (1.7, 3.7) 1.9 (1.1, 3.3)
Overall 66/133 (50) 4.5 (3.6, 5.8) 49/158 (31) 2.2 (1.6, 2.9) 2.1 (1.5, 3.0)
a Age at enrolment
bMissing data for one individual
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[24]. In the much smaller proportion (17%) of HIV-2
infected subjects in Caio with a high viral load (>10,000
copies per ml) these had greatly decreased survival, as has
been found in HIV-1 infection in Bissau and The Gambia
[11,18].
Both HIV-2 plasma viral load and CD4 percentage pre-
dicted survival. The association with HIV-2 plasma viral
load was very strong; and in multivariable analysis mor-
tality among those with plasma viral load exceeding
10,000 HIV-2 RNA copies per ml was 5 fold higher than
in those with undetectable plasma viral load, whose mor-
tality rate was not appreciably different from that in HIV-
2-uninfected subjects. The association between CD4 per-
centage and survival was weaker and lost significance
after adjusting for age, sex and plasma viral load. Our
results confirm those of previous studies showing lower
viral replication in HIV-2, which suggested that HIV-2
plasma viral load may predict prognosis [13,17-20]. We
Figure 2 Kaplan-Meier survival of HIV-2 infected (stratified by baseline plasma viral load) and HIV-uninfected subjects.
Table 4: Association between CD4 percentage, plasma viral load measured in 1991 and mortality over a 18 year follow-up 
among HIV-2 infected subjects.
Univariable Multivariablea
Number Mortality rate 
per 100 
person-years
(95% CI)
Rate ratio
(95% CI)
Rate ratio
(95% CI)
P value
Plasma viral load b, copies per ml
≤ 100 15/48 (31) 2.4 (1.4, 4.0) 1.0 <0.001 1 <0.001
101-
10,000
31/60 (52) 4.9 (3.5, 7.0) 2.0 (1.1, 3.8) 2.0 (1.0, 4.2)
>10,000 18/22 (82) 10.4 (6.6, 16.5) 4.3 (2.2, 8.6) 5.6 (2.5, 12.5)
CD4 percentage c
≥ 28% 26/70 (37) 3.1 (2.1, 4.6) 1.0 0.007 1 0.2
<28% 34/55 (62) 6.3 (4.5, 8.8) 2.0 (1.2, 3.3) 1.4 (0.8, 2.5)
a Adjusted for age category, sex, CD4 percentage and plasma viral load
b Missing data for 3 individuals
c Missing data for 8 individuals
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are unable to say with certainty how plasma viral load
changed over time in those who died since our sampling
was not done with sufficient frequency. However, in the
small number tested there was a large but statistically
non-significant rise in plasma viral load (median increase
20,000 copies/ml) in the 12 year period before their
death.
Importantly, and for the first time, we have shown that
amongst the survivors who were followed-up successfully
and did not seroconvert to HIV-1, plasma viral load did
not change appreciably over the 18 years of follow-up.
Thus, there is a substantial proportion of individuals in
HIV-2 infection in whom viral load remains set and stable
at a very low level over decades, compared to the much
higher set points typically described for HIV-1 [25].
Understanding the biological significance of this observa-
tion seems key to unravelling differences in the enhanced
survival of the majority of HIV-2 subjects compared to
HIV-1. Both host genetic and viral factors are likely to be
important. The same HIV-2 subjects with a low or unde-
tectable viral load and a normal CD4 percentage have
been shown to have strong T-cell responses to the HIV-2
gag protein, particularly directed towards the highly con-
served region represented by peptide 46 in the Major
Homology Region [23,26]. The findings raise the intrigu-
ing possibility of developing a therapeutic vaccine tar-
geted at the gag epitopes identified in this study for the
treatment of those with progressive disease. As viral load
is already well controlled in the majority of subjects, the
chances of success may be higher than in HIV-1 infection.
However, there remains a small proportion of subjects
where host control of virus infection has failed, in those
with a high viral load and a mortality rate similar to those
with HIV-1 infection. An analogous situation has been
described in wild chimpanzees infected with an SIV
chimpanzee strain (SIVcpz), thought to have evolved after
the transmission of a SIV from red-capped sooty mang-
abey monkeys [27], where a higher viral load also corre-
lates with mortality. Current research based on the
cohort suggests that high viral load is associated with
HLA B*1503 subtype which is common in the Manjago
ethnic group and confined to populations in sub-Saharan
Africa [28]. A previous study of viral genotype in Caio vil-
lage in which sequencing was limited to a small propor-
tion of the genome, suggested that viral genotype
determined disease progression and that virulence fac-
tors are multiple and scattered through out the genome
[29]. A recent analysis of HIV-2 p26 capsid variation in
Table 5: Changes in HIV-2 plasma viral load and CD4 percentage over time.
1991
(N = 133)
1996
(N = 97)
2003
(N = 47)
2006
(N = 31)
Plasma viral load, copies ml
Median (IQR)a 348 (50, 4,300) 150 (50, 1,554) 203 (50, 2,837) 171 (50, 497)
Median change 
(IQR)b
N/A 0 (-140, 825) 0 (0, 1,534) 0 (-2, 373)
Category, number 
(%)
<100 48 (36) 33 (42) 20 (43) 13 (42)
100-9,999 60 (45) 32 (41) 19(40) 16 (52)
≥ 10,000 22 (17) 12 (15) 8 (17) 2 (6)
Not tested 3 (2) 1 (1) 0 (0) 0 (0)
CD4+ (% of lymphocytes)
Median (IQR)c 29 (22, 35) 32 (26, 38) 32 (26, 37) 33 (27, 43)
Median change 
(IQR)d
N/A 3 (-4, 8) 3 (-1, 8) 5 (-2, 9)
Category
≥ 28% 70 (53) 48 (61) 28 (60) 22 (71)
<28% 55 (41) 25 (32) 16 (34) 9 (29)
Not tested 8 (6) 5 (6) 3 (6) 0 (0)
a Data were available for 130 subjects in 1991, 77 in 1996, 47 in 2003 and 38 in 2006
b Median change compared to previous time point. Data were available at both time points for 76 subjects in 1996, 42 in 2003 and 26 in 2006
c Data were available for 125 subjects in 1991, 73 in 1996, 44 in 2003 and 31 in 2006
d Median change compared to previous time point. Data were available at both time points for 69 subjects in 1996, 31 in 2003 and 26 in 2006
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plasma viral sequences rescued from this cohort has
shown that a proline in positions 119, 159 and178 in the
capsid protein predicts a low viral load. Conversely if
other amino acids are occupying these positions the viral
load is high [30]. The study raises interesting questions as
to how the low-replicating proline mutants are main-
tained in the population, as transmission is strongly
related to viral load.
Conclusion
This unique field study of HIV-2 infection in a rural com-
munity demonstrates the power of coupling good epide-
miological data with detailed laboratory investigations.
Divergent patterns of viral pathogenicity have resulted in
two distinct clinical outcomes which provide a great
opportunity to examine the key elements of host protec-
tion and viral virulence. Further studies need to be
informed by complete sequencing of host and viral
genomes and a deeper understanding of their phenotypic
interactions. Such basic knowledge is sorely needed to
understand correlates of immunity and their effect on the
evolution of the virus, which will inform the design of
HIV vaccines which to date have met with little success.
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